ERSBURG, Md.--(BUSINESS WIRE)--MaxCyte today announces the launch of the MaxCyte® GT™ Flow Transfection System to academic and clinical investigators. The MaxCyte® GT™ Flow Transfection System is a validated platform for optimizing the biological activity of cellular therapeutic products. The system, which is supported by US FDA Master File and CE marking, enables rapid and efficient transfection of any primary cell or cell line to achieve greater than 90% cell viability. A broad range of molecules (protein, drug, plasmid, mRNA, or siRNA) or combinations thereof, at volumes up to tens of billion cells, can be processed in less than 30 minutes. The system permits rapid, automated, cGMP-compliant, closed system cell processing for both cGMP facility and point-of-care use. The MaxCyte® GT™ Flow Transfection System enables cost-effective delivery with both autologous and allogeneic cellular therapies, customized for enhanced efficacy.
